Mankind Pharma has agreed to acquire a 70% stake in Belgium's Armed Cell Therapeutics for €48 million, marking its entry into next-generation CAR-T oncology therapies.

Ori Biotech has entered a 10-year commercial partnership worth up to $120 million to integrate its IRO automated manufacturing platform into production of an autologous cell therapy.

Sernova and Seraxis have entered into a definitive merger agreement to create BetaNova Biotherapeutics, a new clinical-stage company focused on type 1 diabetes islet-cell replacement therapies.

Sudarshan Pharma has approved the acquisition of a 9.5% stake in US-based MedTherapy Biotechnology, expanding its exposure to oncology cell and gene therapy.

TScan Therapeutics is cutting approximately 75% of its workforce and pausing further enrolment in its Phase 3 ALLOHA-2 study as it redirects resources towards in vivo cell therapy programmes for solid tumours.

ArsenalBio is cutting 99 jobs as it restructures the company around a strategic shift towards in vivo CAR-T development.

BMS concluded that Cellares’ automated Cell Shuttle platform could not meet the specific requirements for commercial Breyanzi production, prompting Cellares to cut around 100 positions.

The completed acquisition adds MediSix’s PEBL T-cell engineering technology, clinical pipeline and Singapore-based R&D team to IASO Bio’s existing cell therapy development, manufacturing and commercial capabilities.

The FDA has approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy to improve chronic graft-versus-host disease (GVHD)-free survival in adults with blood cancers